- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00552058
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
10. července 2018 aktualizováno: UCB Pharma
Phase IIIb, Multinational, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-Tumor Necrosis Factor(TNF)-Alpha Monoclonal Antibody, Administered in Subjects With Moderately to Severely Active Crohn's Disease.
The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.
Přehled studie
Postavení
Dokončeno
Podmínky
Intervence / Léčba
Typ studie
Intervenční
Zápis (Aktuální)
439
Fáze
- Fáze 3
Rozšířený přístup
Dostupný mimo klinické hodnocení.
Viz rozšířený záznam o přístupu.
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
-
Adelaide, Austrálie
-
Bankstown, Austrálie
-
Clayton, Austrálie
-
Fitzroy, Austrálie
-
Fremantle, Austrálie
-
Garran, Austrálie
-
-
New South Wales
-
Concord, New South Wales, Austrálie
-
-
Victoria
-
Box Hill, Victoria, Austrálie
-
Footscray, Victoria, Austrálie
-
Parkville, Victoria, Austrálie
-
-
-
-
-
Bonheiden, Belgie
-
Brussels, Belgie
-
Gent, Belgie
-
Leuven, Belgie
-
Liege, Belgie
-
Roeselare, Belgie
-
-
-
-
-
Curitiba, Brazílie
-
Goiania, Brazílie
-
Porto Alegre, Brazílie
-
Rio de Janeiro, Brazílie
-
Santo-Andre, Brazílie
-
Santos, Brazílie
-
Sao Paulo, Brazílie
-
-
MG
-
Belo-Horizonte, MG, Brazílie
-
-
-
-
-
Santiago, Chile
-
Vina del Mar, Chile
-
-
-
-
-
Tallin, Estonsko
-
Tartu, Estonsko
-
-
-
-
-
Mikkeli, Finsko
-
-
-
-
-
Bologna, Itálie
-
Padova, Itálie
-
Roma, Itálie
-
-
-
-
-
Beer Sheva, Izrael
-
Haifa, Izrael
-
Holon, Izrael
-
Jerusalem, Izrael
-
Kfar Saba, Izrael
-
Petha Tikva, Izrael
-
Rehovot, Izrael
-
Tel Aviv, Izrael
-
Zerifin, Izrael
-
-
-
-
-
Calgary, Kanada
-
-
Alberta
-
Edmonton, Alberta, Kanada
-
-
British Columbia
-
Kelowna, British Columbia, Kanada
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada
-
-
Ontario
-
Hamilton, Ontario, Kanada
-
Kingston, Ontario, Kanada
-
London, Ontario, Kanada
-
Toronto, Ontario, Kanada
-
-
-
-
-
Riga, Lotyšsko
-
Valmiera, Lotyšsko
-
-
-
-
-
Budapest, Maďarsko
-
Gyor, Maďarsko
-
Nagykanizsa, Maďarsko
-
Szeged, Maďarsko
-
Szombathely, Maďarsko
-
-
-
-
-
Auckland, Nový Zéland
-
Christchurch, Nový Zéland
-
Hamilton, Nový Zéland
-
-
Auckland
-
Milford, Auckland, Nový Zéland
-
-
Wellington
-
Newton, Wellington, Nový Zéland
-
-
-
-
-
Berlin, Německo
-
Frankfurt, Německo
-
Freiburg, Německo
-
Homburg, Německo
-
Jena, Německo
-
Kiel, Německo
-
Munchen, Německo
-
Ulm, Německo
-
Wilhelmshaven, Německo
-
-
-
-
-
Czestochowa, Polsko
-
Lodz, Polsko
-
Warszawa, Polsko
-
Wroclaw, Polsko
-
-
-
-
-
Wien, Rakousko
-
-
-
-
-
Bucharest, Rumunsko
-
Cluj Napoca, Rumunsko
-
Constanta, Rumunsko
-
-
-
-
-
Kazan, Ruská Federace
-
Moscow, Ruská Federace
-
St. Petersburg, Ruská Federace
-
-
-
-
Alabama
-
Pell City, Alabama, Spojené státy
-
-
Colorado
-
Colorado Springs, Colorado, Spojené státy
-
Lakewood, Colorado, Spojené státy
-
Littleton, Colorado, Spojené státy
-
-
Florida
-
Hollywood, Florida, Spojené státy
-
Jacksonville, Florida, Spojené státy
-
New Port Richey, Florida, Spojené státy
-
Winter Park, Florida, Spojené státy
-
-
Illinois
-
Chicago, Illinois, Spojené státy
-
-
Kentucky
-
Louisville, Kentucky, Spojené státy
-
-
Louisiana
-
Metairie, Louisiana, Spojené státy
-
Monroe, Louisiana, Spojené státy
-
-
Maryland
-
Annapolis, Maryland, Spojené státy
-
Towson, Maryland, Spojené státy
-
-
Michigan
-
Chesterfield, Michigan, Spojené státy
-
West Bloomfield, Michigan, Spojené státy
-
-
Minnesota
-
Rochester, Minnesota, Spojené státy
-
-
North Carolina
-
Raleigh, North Carolina, Spojené státy
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy
-
Cleveland, Ohio, Spojené státy
-
-
Pennsylvania
-
Lancaster, Pennsylvania, Spojené státy
-
-
Tennessee
-
Germantown, Tennessee, Spojené státy
-
-
Virginia
-
Norfolk, Virginia, Spojené státy
-
-
Washington
-
Seattle, Washington, Spojené státy
-
-
-
-
-
Dniepropetrovsk, Ukrajina
-
Donetsk, Ukrajina
-
Kiev, Ukrajina
-
Kyiv, Ukrajina
-
Lviv, Ukrajina
-
Simferopol, Ukrajina
-
-
-
-
-
Hradec Kralove, Česko
-
Hradek Kralove, Česko
-
Praha 7, Česko
-
Usti Nad Orlici, Česko
-
Zlin, Česko
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
18 let až 75 let (Dospělý, Starší dospělý)
Přijímá zdravé dobrovolníky
Ne
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion Criteria:
- male/female
- 18 - 75 years inclusive
- diagnosis of Crohn's disease confirmed
- moderate to severe disease activity (Crohn's Disease Activity Index (CDAI) 225 - 450)
- no previous treatment with anti-tumor necrosis factor (anti-TNF) medications
Exclusion Criteria:
- previous participation in a certolizumab pegol study
- general exclusion criteria as common for studies in this indication
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Certolizumab pegol
Certolizumab pegol 400 mg for subcutaneous (sc) injection
|
Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
Ostatní jména:
|
|
Komparátor placeba: Placebo
Placebo, saline solution for sc injection
|
Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Subjects in Clinical Remission at Week 6
Časové okno: Week 6
|
The percentage of subjects in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Subjects Achieving a Clinical Response at Week 6
Časové okno: Week 0, Week 6
|
The percentage of subjects achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 6
Časové okno: Week 6
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 6 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 6
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 6
Časové okno: Week 0 to Week 6
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 6. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0 to Week 6
|
|
Change in Harvey Bradshaw Index (HBI) Score From Week 0 to Week 6
Časové okno: Week 0 to Week 6
|
The change in Harvey Bradshaw Index (HBI) score from Week 0 to Week 6. HBI score consists of clinical parameters of general well-being (0 to 4), abdominal pain (0 to 3), number of liquid stools per day, abdominal mass (0 to 3), and complications (score 1 per item).
The first three items are scored for the previous day.
Lower scores indicated better well being.
|
Week 0 to Week 6
|
|
Percentage of Subjects in Clinical Remission at Week 2
Časové okno: Week 2
|
The percentage of subjects in clinical remission at Week 2 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 2
|
|
Percentage of Subjects in Clinical Remission at Week 4
Časové okno: Week 4
|
The percentage of subjects in clinical remission at Week 4 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 4
|
|
Percentage of Subjects Achieving a Clinical Response at Week 2
Časové okno: Week 0, Week 2
|
The percentage of subjects achieving a clinical response at Week 2 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 2
|
|
Percentage of Subjects Achieving a Clinical Response at Week 4
Časové okno: Week 0, Week 4
|
The percentage of subjects achieving a clinical response at Week 4 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 4
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 2
Časové okno: Week 0 to Week 2
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 2. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0 to Week 2
|
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 4
Časové okno: Week 0, Week 4
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 4. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 4
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 2
Časové okno: Week 2
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 2 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 2
|
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 4
Časové okno: Week 4
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 4 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 4
|
|
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
Časové okno: Week 6
|
The percentage of subjects in the subgroup with less than 10 mg/L of C-reactive Protein (CRP) at Entry who are in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
|
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
Časové okno: Week 6
|
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
|
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
Časové okno: Week 0, Week 6
|
The percentage of subjects in the subgroup with less than 10 mg/L C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
|
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
Časové okno: Week 0, Week 6
|
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Sponzor
Publikace a užitečné odkazy
Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.
Obecné publikace
- Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011 Aug;9(8):670-678.e3. doi: 10.1016/j.cgh.2011.04.031. Epub 2011 May 13.
- Sandborn WJ, Melmed GY, McGovern DP, Loftus EV Jr, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015 Aug;42(3):330-42. doi: 10.1111/apt.13251. Epub 2015 Jun 1.
- Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, Kayhan C, Pierre-Louis B, Schreiber S, Lichtenstein GR. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014 Oct;40(8):903-16. doi: 10.1111/apt.12930. Epub 2014 Aug 22.
Užitečné odkazy
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia
1. března 2008
Primární dokončení (Aktuální)
1. října 2009
Dokončení studie (Aktuální)
1. listopadu 2009
Termíny zápisu do studia
První předloženo
18. října 2007
První předloženo, které splnilo kritéria kontroly kvality
31. října 2007
První zveřejněno (Odhad)
1. listopadu 2007
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
9. srpna 2018
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
10. července 2018
Naposledy ověřeno
1. října 2011
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- C87085
- 2007-001913-41 (Číslo EudraCT)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .